Top

Published in:

Open Access 01-12-2007 | Review

World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria

Authors: Christopher V Plowe, Cally Roper, John W Barnwell, Christian T Happi, Hema H Joshi, Wilfred Mbacham, Steven R Meshnick, Kefas Mugittu, Inbarani Naidoo, Ric N Price, Robert W Shafer, Carol H Sibley, Colin J Sutherland, Peter A Zimmerman, Philip J Rosenthal

Published in: Malaria Journal | Issue 1/2007

Abstract

Molecular markers for drug resistant malaria represent public health tools of great but mostly unrealized potential value. A key reason for the failure of molecular resistance markers to live up to their potential is that data on the their prevalence is scattered in disparate databases with no linkage to the clinical, in vitro and pharmacokinetic data that are needed to relate the genetic data to relevant phenotypes. The ongoing replacement of older monotherapies for malaria by new, more effective combination therapies presents an opportunity to create an open access database that brings together standardized data on molecular markers of drug resistant malaria from around the world. This paper presents a rationale for creating a global database of molecular markers for drug resistant malaria and for linking it to similar databases containing results from clinical trials of drug efficacy, in vitro studies of drug susceptibility, and pharmacokinetic studies of antimalarial drugs, in a World Antimalarial Resistance Network (WARN). This database will be a global resource, guiding the selection of first line drugs for treating uncomplicated malaria, for preventing malaria in travelers and for intermittent preventive treatment of malaria in pregnant women, infants and other vulnerable groups. Perhaps most important, a global database for molecular markers of drug resistant malaria will accelerate the identification and validation of markers for resistance to artemisinin-based combination therapies and, thereby, potentially prolong the useful therapeutic lives of these important new drugs.

Available only for authorised users

Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT: Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000, 6: 861-871. 10.1016/S1097-2765(05)00077-8.CrossRefPubMedPubMedCentral

Sidhu AB, Verdier-Pinard D, Fidock DA: Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science. 2002, 298: 210-213. 10.1126/science.1074045.CrossRefPubMedPubMedCentral

Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF: Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature. 2000, 403: 906-909. 10.1038/35002615.CrossRefPubMed

Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ: The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob Agents Chemother. 1999, 43: 2943-2949.PubMedPubMedCentral

Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L: Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004, 364: 438-447. 10.1016/S0140-6736(04)16767-6.CrossRefPubMedPubMedCentral

Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC: The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol Biochem Parasitol. 2000, 108: 13-23. 10.1016/S0166-6851(00)00201-2.CrossRefPubMed

Peterson DS, Walliker D, Wellems TE: Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA. 1988, 85: 9114-9118. 10.1073/pnas.85.23.9114.CrossRefPubMedPubMedCentral

Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE: Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem. 1994, 224: 397-405. 10.1111/j.1432-1033.1994.00397.x.CrossRefPubMed

Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y: A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med. 2001, 344: 257-263. 10.1056/NEJM200101253440403.CrossRefPubMed

10.

Djimde A, Doumbo OK, Steketee RW, Plowe CV: Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet. 2001, 358: 890-891. 10.1016/S0140-6736(01)06040-8.CrossRefPubMed

11.

Djimde AA, Dolo A, Ouattara A, Diakite S, Plowe CV, Doumbo OK: Molecular diagnosis of resistance to antimalarial drugs during epidemics and in war zones. J Infect Dis. 2004, 190: 853-855. 10.1086/422758.CrossRefPubMed

12.

Mugittu K, Ndejembi M, Malisa A, Lemnge M, Premji Z, Mwita A: Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance. Am J Trop Med Hyg. 2004, 71: 696-702.PubMed

13.

Kublin JG, Cortese JF, Njunju EM, RA GM, Wirima JJ, Kazembe PN: Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003, 187: 1870-1875. 10.1086/375419.CrossRefPubMed

14.

White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW: Averting a malaria disaster. Lancet. 1999, 353: 1965-1967. 10.1016/S0140-6736(98)07367-X.CrossRefPubMed

15.

Bzik DJ, Li W, Horii T, Inselburg J: Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci USA. 1987, 84: 8360-8364. 10.1073/pnas.84.23.8360.CrossRefPubMedPubMedCentral

16.

Foote SJ, Thompson JK, Cowman AF, Kemp DJ: Amplification of the multidrug resistance gene in some chloroquine-resistant isolates of P. falciparum. Cell. 1989, 57: 921-930. 10.1016/0092-8674(89)90330-9.CrossRefPubMed

17.

Wellems TE, Walker-Jonah A, Panton LJ: Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7. Proc Natl Acad Sci USA. 1991, 88: 3382-3386. 10.1073/pnas.88.8.3382.CrossRefPubMedPubMedCentral

18.

Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ: Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature. 1990, 345: 255-258. 10.1038/345255a0.CrossRefPubMed

19.

Cowman AF, Galatis D, Thompson JK: Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci USA. 1994, 91: 1143-1147. 10.1073/pnas.91.3.1143.CrossRefPubMedPubMedCentral

20.

Price RN, Uhlemann AC, van VM, Brockman A, Hutagalung R, Nair S: Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis. 2006, 42: 1570-1577. 10.1086/503423.CrossRefPubMedPubMedCentral

21.

Wu Y, Kirkman L, Wellems TE: Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Proc Natl Acad Sci USA. 1996, 93: 1130-1134. 10.1073/pnas.93.3.1130.CrossRefPubMedPubMedCentral

22.

Wooden JM, Hartwell LH, Vasquez B, Sibley CH: Analysis in yeast of antimalaria drugs that target the dihydrofolate reductase of Plasmodium falciparum. Mol Biochem Parasitol. 1997, 85: 25-40. 10.1016/S0166-6851(96)02808-3.CrossRefPubMed

23.

Cortese JF, Plowe CV: Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutants expressed in yeast. Mol Biochem Parasitol. 1998, 94: 205-214. 10.1016/S0166-6851(98)00075-9.CrossRefPubMed

24.

Plowe CV, Cortese JF, Djimde A, Nwanyanwu OC, Watkins WM, Winstanley PA: Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis. 1997, 176: 1590-1596.CrossRefPubMed

25.

Wang P, Lee CS, Bayoumi R, Djimde A, Doumbo O, Swedberg G: Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol Biochem Parasitol. 1997, 89: 161-177. 10.1016/S0166-6851(97)00114-X.CrossRefPubMed

26.

Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM: Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002, 185: 380-388. 10.1086/338566.CrossRefPubMed

27.

Djimde AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y: Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2003, 69: 558-563.PubMed

28.

White NJ: Why is it that antimalarial drug treatments do not always work?. Annals of Tropical Medicine & Parasitology. 1998, 92: 449-458. 10.1080/00034989859429.CrossRef

29.

Dzinjalamala FK, Macheso A, Kublin JG, Taylor TE, Barnes KI, Molyneux ME: Blood folate concentrations and in vivo sulfadoxine-pyrimethamine failure in Malawian children with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2005, 72: 267-272.PubMed

30.

Francis D, Nsobya SL, Talisuna A, Yeka A, Kamya MR, Machekano R: Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis. 2006, 193: 978-986. 10.1086/500951.CrossRefPubMed

31.

Tinto H, Sanou B, Dujardin JC, Ouedraogo JB, VAN OC, Erhart A: Usefulness of the Plasmodium falciparum chloroquine resistance transporter T76 genotype failure index for the estimation of in vivo chloroquine resistance in Burkina Faso. Am J Trop Med Hyg. 2005, 73: 171-173.PubMed

32.

Kyabayinze D, Cattamanchi A, Kamya MR, Rosenthal PJ, Dorsey G: Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am J Trop Med Hyg. 2003, 69: 247-252.PubMed

33.

Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B: Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet. 2005, 366: 1960-1963. 10.1016/S0140-6736(05)67787-2.CrossRefPubMed

34.

Mu J, Ferdig MT, Feng X, Joy DA, Duan J, Furuya T: Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol Microbiol. 2003, 49: 977-989. 10.1046/j.1365-2958.2003.03627.x.CrossRefPubMed

35.

Volkman SK, Sabeti PC, Decaprio D, Neafsey DE, Schaffner SF, Milner DA: A genome-wide map of diversity in Plasmodium falciparum. Nat Genet. 2007, 39: 113-119. 10.1038/ng1930.CrossRefPubMed

36.

Jeffares DC, Pain A, Berry A, Cox AV, Stalker J, Ingle CE: Genome variation and evolution of the malaria parasite Plasmodium falciparum. Nat Genet. 2007, 39: 120-125. 10.1038/ng1931.CrossRefPubMed

37.

Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE: Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995, 52: 565-568.PubMed

38.

Rojanawatsirivej C, Vijaykadga S, Amklad I, Wilairatna P, Looareesuwan S: Monitoring the therapeutic efficacy of antimalarials against uncomplicated falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health. 2003, 34: 536-541.PubMed

39.

Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN: Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006, 11: 1800-1807. 10.1111/j.1365-3156.2006.01739.x.CrossRefPubMed

40.

Alker AP, Lim P, Sem R, Shah NK, Yi P, Bouth DM: Pfmdr1 and in vivo resistance to artesunate-mefloquine in Falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg. 2007, 76: 641-647.PubMed

41.

Bloland PB, Lackritz EM, Kazembe PN, Were JB, Steketee R, Campbell CC: Beyond chloroquine: implications of drug resistance for evaluating malaria therapy efficacy and treatment policy in Africa. J Infect Dis. 1993, 167: 932-937.CrossRefPubMed

42.

Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL: Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006, 355: 1959-1966. 10.1056/NEJMoa062032.CrossRefPubMed

43.

Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, Staedke SG: Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet. 2002, 360: 2031-2038. 10.1016/S0140-6736(02)12021-6.CrossRefPubMed

44.

Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde RT: Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet. 2007, 369: 491-498. 10.1016/S0140-6736(07)60236-0.CrossRefPubMed

45.

Rogerson SJ, Chaluluka E, Kanjala M, Mkundika P, Mhango C, Molyneux ME: Intermittent sulfadoxine-pyrimethamine in pregnancy: effectiveness against malaria morbidity in Blantyre, Malawi, in 1997–99. Trans R Soc Trop Med Hyg. 2000, 94: 549-553. 10.1016/S0035-9203(00)90083-X.CrossRefPubMed

46.

Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, Tanner M: Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: a randomised, placebo-controlled trial. Lancet. 2001, 357: 1471-1477. 10.1016/S0140-6736(00)04643-2.CrossRefPubMed

47.

Hamel MJ, Holtz T, Mkandala C, Kaimila N, Chizani N, Bloland P: Efficacy of trimethoprim-sulfamethoxazole compared with sulfadoxine-pyrimethamine plus erythromycin for the treatment of uncomplicated malaria in children with integrated management of childhood illness dual classifications of malaria and pneumonia. Am J Trop Med Hyg. 2005, 73: 609-615.PubMed

48.

Mermin J, Bunnell R, Lule J, Opio A, Gibbons A, Dybul M: Developing an evidence-based, preventive care package for persons with HIV in Africa. Trop Med Int Health. 2005, 10: 961-970. 10.1111/j.1365-3156.2005.01488.x.CrossRefPubMed

49.

Thera MA, Sehdev PS, Coulibaly D, Traore K, Garba MN, Cissoko Y: Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis. 2005, 192: 1823-1829. 10.1086/498249.CrossRefPubMedPubMedCentral

50.

Iyer JK, Milhous WK, Cortese JF, Kublin JG, Plowe CV: Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet. 2001, 358: 1066-1067. 10.1016/S0140-6736(01)06201-8.CrossRefPubMed

51.

Triglia T, Wang P, Sims PF, Hyde JE, Cowman AF: Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO J. 1998, 17: 3807-3815. 10.1093/emboj/17.14.3807.CrossRefPubMedPubMedCentral

52.

Malamba SS, Mermin J, Reingold A, Lule JR, Downing R, Ransom R: Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members. Am J Trop Med Hyg. 2006, 75: 375-380.PubMed

53.

Laufer MK, Plowe CV: Cotrimoxazole prophylaxis and malaria in Africa: Have the important questions been answered?. Am J Trop Med Hyg. 2006, 75: 373-374.PubMed

54.

Laufer MK, Plowe CV: Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. Drug Resist Updat. 2004, 7: 279-288. 10.1016/j.drup.2004.08.003.CrossRefPubMed

55.

Dokomajilar C, Lankoande ZM, Dorsey G, Zongo I, Ouedraogo JB, Rosenthal PJ: Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am J Trop Med Hyg. 2006, 75: 162-165.PubMed

56.

Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, Sutherland CJ: Amodiaquine and artemether-lumefantrine select distinct alleles of the P. falciparum pfmdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob Agents Chemother. 2006

57.

Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A: In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis. 2005, 191: 1014-1017. 10.1086/427997.CrossRefPubMed

58.

Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G: Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob Agents Chemother. 2006, 50: 1893-1895. 10.1128/AAC.50.5.1893-1895.2006.CrossRefPubMedPubMedCentral

59.

Ferdig MT, Cooper RA, Mu J, Deng B, Joy DA, Su XZ: Dissecting the loci of low-level quinine resistance in malaria parasites. Mol Microbiol. 2004, 52: 985-997. 10.1111/j.1365-2958.2004.04035.x.CrossRefPubMed

60.

Mu J, Awadalla P, Duan J, McGee KM, Keebler J, Seydel K: Genome-wide variation and identification of vaccine targets in the Plasmodium falciparum genome. Nat Genet. 2007, 39: 126-130. 10.1038/ng1924.CrossRefPubMed

61.

Jelinek T, Peyerl-Hoffmann G, Muhlberger N, Wichmann O, Wilhelm M, Schmider N: Molecular surveillance of drug resistance through imported isolates of Plasmodium falciparum in Europe. Malar J. 2002, 1: 11-10.1186/1475-2875-1-11.CrossRefPubMedPubMedCentral

62.

Labbe AC, Patel S, Crandall I, Kain KC: A molecular surveillance system for global patterns of drug resistance in imported malaria. Emerg Infect Dis. 2003, 9: 33-36.CrossRefPubMedPubMedCentral

63.

Schwartz E, Bujanover S, Kain KC: Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin Infect Dis. 2003, 37: 450-451. 10.1086/375599.CrossRefPubMed

64.

Wu Y, Fairfield AS, Oduola A, Cypess RH: The Malaria Research and Reference Reagent Resource (MR4) Center – creating African opportunities. Afr J Med Med Sci. 2001, 30 (Suppl): 52-54.PubMed

65.

Baird JK, Basri H, Purnomo , Bangs MJ, Subianto B, Patchen LC: Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg. 1991, 44: 547-552.PubMed

66.

Eldin de Pecoulas P, Tahar R, Ouatas T, Mazabraud A, Basco LK: Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol Biochem Parasitol. 1998, 92: 265-273. 10.1016/S0166-6851(97)00247-8.CrossRef

67.

Auliff A, Wilson DW, Russell B, Gao Q, Chen N, Anh lN: Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. Am J Trop Med Hyg. 2006, 75: 617-621.PubMed

68.

Mapping Malaria Risk in Africa. [http://www.mara.org.za]

Title: World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria
Authors: Christopher V Plowe
Cally Roper
John W Barnwell
Christian T Happi
Hema H Joshi
Wilfred Mbacham
Steven R Meshnick
Kefas Mugittu
Inbarani Naidoo
Ric N Price
Robert W Shafer
Carol H Sibley
Colin J Sutherland
Peter A Zimmerman
Philip J Rosenthal
Publication date: 01-12-2007
Publisher: BioMed Central
Published in: Malaria Journal / Issue 1/2007
Electronic ISSN: 1475-2875
DOI: https://doi.org/10.1186/1475-2875-6-121

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2007

The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics

Effect of discriminative plant-sugar feeding on the survival and fecundity of Anopheles gambiae

Congenital malaria with atypical presentation: A case report from low transmission area in India

Diagnosis and treatment of malaria in peripheral health facilities in Uganda: findings from an area of low transmission in south-western Uganda

Comparison of three molecular methods for the detection and speciation of Plasmodium vivax and Plasmodium falciparum

Changes in var gene mRNA levels during erythrocytic development in two phenotypically distinct Plasmodium falciparum parasites

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page